Engineered viral vector manufacturing — the same platform fuels ex-vivo cell therapy and in-vivo gene therapy programs. Adherent and suspension, research scale through GMP, all under one roof.
GMP lentiviral and gamma-retroviral vector as bulk drug substance or finished drug product — for in vivo therapies dosed directly to patients, and as starting material for ex vivo cell therapy.
Purified, concentrated vector manufactured under cGMP — the active ingredient for in vivo programs and the critical starting material for ex vivo cell therapies.
Formulated, filled, and released vector ready for clinical administration — including in vivo LVV and in vivo CAR-T therapies dosed directly to patients.
From the first IND-enabling lot to commercial supply — adherent for proven processes, suspension for scalable economics. We engage at any scale and grow with you.
The full viral vector toolbox — chosen to fit your construct, your target cell, and your indication.
Third-generation, self-inactivating lentivirus for stable integration in dividing and non-dividing cells. The standard for modern CAR-T, NK, and Treg programs.
Proprietary engineered promoters that drive expression only in the cells that need it — silent everywhere else. Critical for in-vivo dosing safety profiles.
Engineered control elements — kill switches, regulated transgene expression, and ligand-inducible systems — built into the construct to give you on/off control over the therapy after dosing.
We do viral vector as one continuous program with genetic circuit design, process development, analytical methods, GMP manufacturing, and QC release — all in the same building, with the same team.
Payload engineering and producer cell line generation in our SynBio center.
Upstream & downstream process development, method qualification — built for tech transfer success.
Adherent or suspension GMP campaigns in seven Grade B cleanrooms — FDA & EU standards.
In-house qualified analytics — RCR/RCL, titer, identity, potency. No outsourced wait.
The full set of capabilities that make up our integrated CDMO platform.
SynBio research, ML-driven optimization, proprietary tools for next-gen therapies.
End-to-end autologous & allogeneic workflows — CAR-T, NK, Treg, in-vivo GT.
Engineering, Master & Working cell banks. Adherent & suspension, run in parallel.
Knowledge transfer as a discipline. Development-to-GMP in ~7 months.
Dedicated PMO, transparent Gantts, real-time data exchange. One accountable team.
